All In Biotech

Free tool

FAERS Monitor: Licart

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206976 or its brand name (Licart, Diclofenac Epolamine). Reports on generic versions are filed under their own applications.

Reports

701

Serious

264

38% of reports

Hospitalization

94

Death reported

32

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug hypersensitivity183
  • drug ineffective105
  • pain53
  • off label use41
  • congenital anomaly34
  • fatigue33
  • malaise30
  • headache29
  • diarrhoea28
  • dyspnoea28
  • foetal exposure during pregnancy26
  • nasopharyngitis26
  • nausea26
  • abdominal discomfort25
  • pruritus24

Reports by year received

View as table
YearReports
20041
20071
20101
20112
201221
201320
201426
201538
201627
201726
201866
2019103
202072
202158
202257
202336
202443
202571
202632

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,458 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
congenital anomalySignal34132.495.34,285
drug hypersensitivitySignal18328.425.14,850
foetal exposure during pregnancySignal269.66.6192
abdominal discomfortSignal254.53.064
nasopharyngitisSignal264.22.962
painSignal532.62.052
drug ineffectiveSignal1052.42.089
malaiseSignal302.11.415
pruritus241.91.39
dyspnoea281.51.04
off label use411.41.05
headache291.41.03
diarrhoea281.30.92
fatigue331.30.92
nausea261.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.